Walvax Biotechnology Halts EV71 Vaccine Development Amid Changing Disease Trends
China’s Walvax Biotechnology Co., Ltd (SHE: 300142) has announced the decision to terminate a clinical...
Company
Jiangsu Hengrui Medicine’s Hetrombopag Olamine Receives FDA Orphan Drug Designation for ITP
China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) has announced that it has received orphan...
WuXi AppTec Faces Shareholder Divestment of Up to 3% Stake
China-based Contract Research Organization (CRO) WuXi AppTec Co., Ltd (SHA: 603259, HKG: 2359) has disclosed...
Zai Lab Ltd Makes FcRn Antagonist Efgartigimod Available for Myasthenia Gravis Treatment
Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) has announced the availability of efgartigimod, the world’s...
Bristol-Myers Squibb Launches Reblozyl in China for β-Thalassemia Treatment
US pharmaceutical giant Bristol-Myers Squibb (BMS; NYSE: BMY) has announced the commercial launch of its...
China NT Pharma Group Company Ltd Inks Licensing Deal for Monoclonal Antibodies
China-based China NT Pharma Group Company Ltd (HKG: 1011) has announced a potential acquisition agreement...
Clover Biopharmaceuticals Initiates SCB-219M Clinical Study for CIT Treatment
China-based Clover Biopharmaceuticals Ltd (HKG: 2197) has announced the first subject dosing in a Phase...
Ferring and I-Mab Expand Olamkicept Collaboration for Inflammatory Diseases
Swiss pharmaceutical company Ferring Pharmaceuticals has announced a strategic collaboration with China’s I-Mab Inc. (NASDAQ:...
Shanghai Henlius Partners with Organon for Global Biosimilar Commercialization
China-based Shanghai Henlius Biotech, Inc. (HKG: 2696) has entered into a licensing and supply agreement...
BeiGene’s Brukinsa Faces Three-Month FDA Approval Delay for CLL/SLL Indication
China-based biotech company BeiGene Inc. (Nasdaq: BGNE) will experience a three-month delay in its pursuit...
Junshi Biosciences Receives NMPA Approval for Fourth-Generation EGFR Inhibitor WJ13404
Shanghai-based biotech Junshi Biosciences (HKG: 1877, SHA: 688180) has received approval from China’s National Medical...
Innovent Biologics Receives BPOM Approval for Bevagen in Indonesia
China-based Innovent Biologics Inc. (HKG: 1801) has announced receiving indication approvals from Indonesia’s Badan Pengawas...
Innovent Biologics’ IBI306 Accepted for Review by China’s NMPA for Hypercholesterolemia
China-based Innovent Biologics Inc. (HKG: 1801) has announced that a New Drug Application (NDA) filing...
Clover Biopharmaceuticals Begins Phase III Trial for COVID-19 Booster SCB-2019
China-based Clover Biopharmaceuticals Ltd (HKG: 2197) has announced the immunization of the first group of...
InventisBio’s KRAS G12C Inhibitor D-1553 Earns CDE Breakthrough Therapy Status
China-based InventisBio (Shanghai) Co., Ltd announced receiving breakthrough therapy designation (BTD) status for its KRAS...
CANbridge Pharmaceuticals Presents Positive Phase I Data for CAN106 at EHA Congress
China-based rare disease firm CANbridge Pharmaceuticals Inc. (HKG: 1228) released the latest data from a...
Zai Lab’s Repotrectinib Earns Two Breakthrough Therapy Designations in China for ROS1+ NSCLC
China-based biopharma Zai Lab Ltd (NASDAQ: ZLAB) announced receiving two breakthrough therapy designations (BTDs) from...
OnCusp Therapeutics Licenses Multitude’s CDH6 ADC for Global Development
US-based OnCusp Therapeutics has entered into a licensing agreement with China’s Multitude Therapeutics for the...
Ascentage Pharma’s Lisaftoclax Shows Promising Results in Phase I Trial for Non-Hodgkin Lymphoma
Suzhou-based Ascentage Pharma (HKG: 6855) announced the publication of Phase I clinical study results for...
Kangpu Biopharmaceuticals Begins Phase IIa Trial of KPG-818 for Systemic Lupus Erythematosus
Shanghai-based Kangpu Biopharmaceuticals, Ltd has announced the first patient dosing in a multicenter, randomized, double-blind,...